Drug Safety

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

InflaRx
InflaRxJENA, Germany
1 program
1
CaCP29, a humanized monoclonal antibodyPhase 11 trial
Active Trials
NCT01319903Completed26Est. Oct 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InflaRxCaCP29, a humanized monoclonal antibody

Clinical Trials (1)

Total enrollment: 26 patients across 1 trials

NCT01319903InflaRxCaCP29, a humanized monoclonal antibody

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Start: Mar 2011Est. completion: Oct 201126 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space